David E. Goldgar, Ph.D.

Languages

  • English
  • French
  • Spanish

Academic Information

  • Departments: Dermatology - Research Professor, Family and Preventive Medicine - Adjunct Professor
  • Divisions: Physician Assistant Program
  • Cancer Center Programs: Cancer Control & Population Sciences

Academic Office Information

  • (801) 581-6465
  • Huntsman Cancer Institute
    2000 Circle of Hope
    Salt Lake City, UT 84112

Academic Bio

David Goldgar, PhD, is a research professor in the Department of Dermatology at the University of Utah and member of the Cancer Control and Population Sciences (CCPS) Program at Huntsman Cancer Institute.

Goldgar's research involves the genetic study of breast cancer and melanoma. He studies methods to clinically classify the BRCA1 and BRCA2 genes, the most well-known genes for breast cancer.

Before leaving the University of Utah to assume the position of chief of the Genetic Epidemiology Unit at the International Association of Cancer Research in Lyon, France, Goldgar was a member of the team that led to the localization, cloning, or characterization of the cancer predisposing BRCA1, BRCA2, and CDKN2A (p16) mutations. Goldgar joined the CCPS Program in 2008 upon his return to the University of Utah.

Goldgar earned a bachelor's degree and PhD from the University of Colorado, Boulder.

Education History

Type School Degree
Doctoral Training University of Colorado Medical Center
Biostatistics
Ph.D.
Graduate Training Colorado State University
Statistics
M.S.
Undergraduate University of Colorado
Mathematics
B.A.

Global Impact

Selected Publications

Journal Article

  1. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.Vogl FD, Badzioch MD, Steele L, Neuhausen SL, Goldgar DE (2007). Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred. Fam Cancer, 6(1), 63-71.
  2. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE (2007). An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res, 9(2), 104.
  3. Stratton MR, Ford D, Neuhausen S, Seal S, Wooster R, Friedman LS, King M-C, Egilsson V, Devilee P, McMarus R, Daly PA, Smith E, Ponder BAJ, Peto J, Cannon-Albright L, Easton D, Goldgar D (1994). Familial male breast cancer is not linked to BRCA1 locus on chromosome 17q. Nature Genetics, 7, 103-106.
  4. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, et al (1992). Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 258(5085), 1148-52.
  5. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds.Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH (1991). Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst, 83(23), 1726-33.

News

Video